Castle Biosciences (CSTL) EPS (Weighted Average and Diluted) (2018 - 2026)
Castle Biosciences' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$0.07 for Q4 2025.
- On a quarterly basis, EPS (Weighted Average and Diluted) fell 121.88% to -$0.07 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.84, a 235.48% decrease, with the full-year FY2025 number at -$0.83, down 233.87% from a year prior.
- EPS (Weighted Average and Diluted) hit -$0.07 in Q4 2025 for Castle Biosciences, down from -$0.02 in the prior quarter.
- Over the last five years, EPS (Weighted Average and Diluted) for CSTL hit a ceiling of $0.32 in Q4 2024 and a floor of -$1.1 in Q1 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.31 across 5 years, with a median of -$0.21 in 2021.
- Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 1066.67% in 2023 and later surged 455.56% in 2024.
- Tracing CSTL's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.25 in 2021, then tumbled by 216.0% to -$0.79 in 2022, then skyrocketed by 88.61% to -$0.09 in 2023, then skyrocketed by 455.56% to $0.32 in 2024, then plummeted by 121.87% to -$0.07 in 2025.
- Business Quant data shows EPS (Weighted Average and Diluted) for CSTL at -$0.07 in Q4 2025, -$0.02 in Q3 2025, and $0.15 in Q2 2025.